{
    "nct_id": "NCT05322577",
    "official_title": "A Phase 1b/2 Study Evaluating the Safety, Tolerability, Efficacy, and Pharmacokinetics of Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer (FORTITUDE-103).",
    "inclusion_criteria": "* Adults with unresectable, locally advanced or metastatic gastric or gastroesophageal junction cancer not amendable to curative therapy.\n* Ability to provide tumor sample, either archival (obtained within 6 months to joining study) or fresh biopsy.\n* For certain arms for Part 1, FGFR2b overexpression positive defined as any FGFR2b 2+/3+ TC determined by centrally performed immunohistochemistry (IHC), based on tumor sample provided.\n* For Part 2, FGFR2b overexpression positive defined as FGFR2b â‰¥10% 2+/3+ TC determined by centrally performed IHC testing, based on tumor sample provided.\n* Easter Cooperative Oncology Group (ECOG) performance score less than or equal to 1.\n* Measurable or non-measurable disease as long as evaluable by Response Evaluation Criteria Solid Tumors (RECIST) version 1.1\n* Participant has no contradictions to CAPOX/SOX plus or minus nivolumab.\n* Adequate organ function.\n* For Part 2, measurable disease according to RECIST v1.1.\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 100 Years",
    "exclusion_criteria": "* Prior treatment for metastatic or unresectable disease (Note: prior adjuvant or neo-adjuvant therapy for local disease is allowed if ended more than 6 months of 1st dose).\n* Prior treatment with any selective inhibitor of fibroblast growth factor - fibroblast growth factor receptor (FGF-FGFR) pathway.\n* Known human epidermal growth factor receptor 2 (HER2) positive\n* Untreated or symptomatic central nervous system (CNS) disease or brain metastases.\n* Peripheral sensory neuropathy greater than or equal to Grade 2.\n* Clinically significant cardiac disease.\n* Other malignancy within the last 2 years (exceptions for definitively treated disease).\n* Chronic or systemic ophthalmological disorders.\n* Major surgery or other investigational study within 28 days of first study treatment dose.\n* Palliative radiotherapy within 14 days of first study treatment dose.\n* Abnormalities of the cornea that may pose an increased risk of developing a corneal ulcer.\n* History or evidence of systemic disease or ophthalmological disorders requiring chronic use of ophthalmic corticosteroids.",
    "miscellaneous_criteria": ""
}